CartilaGen is a pioneering medical company based in Coralville, IA, dedicated to revolutionizing the treatment of osteoarthritis. Their innovative solution involves a routine intra-articular injection procedure of a small-molecule drug into a joint cavity after traumatic injury, effectively preventing the development of posttraumatic osteoarthritis (PTOA). With a vision to target the earliest stage of PTOA development and treat the underlying disease mechanism, CartilaGen's drug-eluting, bioactive hydrogel offers a cost-effective and easily performed solution for patients suffering from cartilage injuries and early-stage osteoarthritis.
Partnering with renowned institutions such as the University of Iowa Hospitals and Clinics, Indiana University Health, and the US Department of Defense's Major Extremity Trauma and Rehabilitation Consortium (METRC), CartilaGen is at the forefront of groundbreaking research and development. Their combined Phase I and IIa clinical trial is scheduled, showcasing their commitment to addressing the major unmet medical need of preventing PTOA and improving the lives of millions affected by this debilitating condition.
Generated from the website